Fig. 2 | Oncogene

Fig. 2

From: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death

Fig. 2

Nelfinavir enhances the cytotoxicity of bortezomib in Tsc2−/− but not in Tsc2+/+ MEFs. a Tsc2+/+ and Tsc2−/− MEFs were treated with either DMSO vehicle, 1 µM MG132, 50 nM bortezomib (BTZ), 20 µM nelfinavir (NFV) alone or in combination where indicated over 24 h. Cells were then subjected to flow cytometry following DRAQ7 staining. DRAQ7 exclusion (below line) represents the viable cell population, while positive DRAQ7 staining (above line) indicates cell death. The number of DRAQ7-stained Tsc2+/+ and Tsc2−/− MEFs are graphed in (b) (n = 3). c Tsc2+/+ and Tsc2−/− MEFs were treated for 24 h with either DMSO, 20 µM nelfinavir (NFV), 50 nM bortezomib (BTZ) as single agents or in combination, as indicated, and then subjected to DNA fragmentation assays (n = 5). d Tsc2+/+ and Tsc2−/− MEFs were treated for 24 h with 20 µM NFV combined with 50 nM BTZ in the presence or absence of 20 μM Z-VAD-FMK and analyzed for cell death by flow cytometry with DRAQ7 staining. The number of DRAQ7-stained Tsc2+/+ and Tsc2−/− MEFs are graphed (n = 3)

Back to article page